SCHEMBL6531977

SCHEMBL6531977

Cc1ccc(C2=C(C(=O)Nc3ccc(NCCc4cccc(N)n4)cc3)CCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 8/20 0.40
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
ATR Q13535 1/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499546 0.91 RAB9A (0.39) TP53POLBTHRBKDM4EALDH1A1
SCHEMBL6491525 0.90 ALDH1A1 (0.38) TP53POLBTHRBKDM4EALDH1A1
SCHEMBL6491821 0.89 CXCR4 (0.41) TP53KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL6501730 0.87 GAA (0.40) TP53POLBTHRBKDM4EALDH1A1
SCHEMBL6679658 0.87 ITGB1 (0.43) TP53POLBTHRBKDM4EALDH1A1
SCHEMBL6489289 0.85 L3MBTL1 (0.46) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL6492282 0.85 NPC1 (0.41) TP53POLBTHRBKDM4EALDH1A1
SCHEMBL6493547 0.85 L3MBTL1 (0.45) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL6490871 0.85 L3MBTL1 (0.45) KDM4EALDH1A1KMT2AMEN1HPGD
SCHEMBL6490864 0.85 L3MBTL1 (0.45) KDM4EALDH1A1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 TP53 3031/4885POLB 1626/4885THRB 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.